Omeros Corporation (NASDAQ:OMER) Receives Average Rating of “Moderate Buy” from Brokerages

Omeros Corporation (NASDAQ:OMER) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $40.3333.

Several analysts recently commented on the company. Wall Street Zen cut Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, April 21st. Zacks Research upgraded Omeros from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Tuesday, April 21st.

Hedge Funds Weigh In On Omeros

Hedge funds have recently modified their holdings of the company. UBS Group AG increased its position in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after purchasing an additional 1,513,893 shares during the period. JPMorgan Chase & Co. increased its position in shares of Omeros by 1,201.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after purchasing an additional 384,168 shares during the period. Coldstream Capital Management Inc. increased its position in shares of Omeros by 107.5% during the 4th quarter. Coldstream Capital Management Inc. now owns 53,605 shares of the biopharmaceutical company’s stock valued at $921,000 after purchasing an additional 27,775 shares during the period. AlphaCore Capital LLC acquired a new position in shares of Omeros during the 4th quarter valued at $303,000. Finally, Avantax Planning Partners Inc. increased its position in shares of Omeros by 30.7% during the 4th quarter. Avantax Planning Partners Inc. now owns 13,200 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 3,100 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Price Performance

OMER opened at $14.38 on Thursday. Omeros has a 12 month low of $2.95 and a 12 month high of $17.65. The stock has a market cap of $1.04 billion, a P/E ratio of -28.76 and a beta of 2.66. The stock’s 50 day moving average price is $12.22 and its 200 day moving average price is $11.35.

Omeros (NASDAQ:OMER) last posted its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.16. The business had revenue of $9.89 million during the quarter, compared to analyst estimates of $10.05 million. Equities analysts anticipate that Omeros will post -1.54 EPS for the current year.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.